Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. by Tarurgi, P. & Averna, M.
Comp. by: PG1397SNijam Stage: Revises1 ChapterID: 0001247081ACC978-0-
12-387025-4 Date:1/3/11 Time:13:18:48
File Path:\\pchns1002z\WOMAT\Production\PRODENV\0000000001\0000024523
\0000000016\0001247081.3d
Acronym:ACC Volume:54004
C
O
R
R
E
C
T
E
D
P
R
O
O
F
HYPOBETALIPOPROTEINEMIA: GENETICS,
BIOCHEMISTRY, AND CLINICAL SPECTRUM
Patrizia Tarugi*,1 and Maurizio Averna†
*Department of Biomedical Sciences, University of Modena and
Reggio Emilia, Modena, Italy
†Department of Clinical Medicine and Emerging Diseases,
University of Palermo, Palermo, Italy
1. Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
2. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
3. Pathways of apoB-Containing Lipoproteins Production . . . . . . . . . . . . . . . . . . . . . . . . 81
3.1. Assembly and Secretion of apoB-Containing Lipoproteins . . . . . . . . . . . . . . . . 81
3.2. Control of the Secretion of apoB-Containing Lipoproteins . . . . . . . . . . . . . . . . 82
3.3. Intracellular Degradation of apoB and Secretion of apoB-Containing
Lipoproteins. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.4. Clearance of apoB-Containing Lipoproteins via LDL-Receptor . . . . . . . . . . . 84
4. Dominant Forms of Primary HBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.1. FHBL Due to Defective Secretion of apoB-Containing Lipoproteins . . . . . . 85
4.2. FHBLDue to Increased Liver Uptake of apoB-Containing Lipoproteins via
LDL-Receptor. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
4.3. Prevalence of Primary FHBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5. Recessive Forms of Primary HBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.1. Abetalipoproteinemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.2. Chylomicron Retention Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
6. Primary Orphan FHBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
7. Spectrum of Clinical Manifestations in Primary HBL. . . . . . . . . . . . . . . . . . . . . . . . . . . 90
8. Main Clinical Issues of FHBL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
8.1. FHBL and Fatty Liver Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
8.2. FHBL and Cardiovascular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
8.3. FHBL and Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
9. Secondary Hypobetalipoproteinemias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
10. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
1Corresponding author: Patrizia Tarugi, e-mail: tarugi@unimore.it
79
0065-2423/11 $35.00 Copyright 2011, Elsevier Inc.
DOI: 10.1016/B978-0-12-387025-4.00004-2 All rights reserved.
ADVANCES IN CLINICAL CHEMISTRY, VOL. 54
Comp. by: PG1397SNijam Stage: Revises1 ChapterID: 0001247081ACC978-0-
12-387025-4 Date:1/3/11 Time:13:18:48
File Path:\\pchns1002z\WOMAT\Production\PRODENV\0000000001\0000024523
\0000000016\0001247081.3d
Acronym:ACC Volume:54004
C
O
R
R
E
C
T
E
D
P
R
O
O
F
Abbreviations
ABL abetalipoproteinemia
apoB apolipoprotein B
CVD cardiovascular disease
CM chylomicron
CMRD chylomicron retention disease
COP coat protein
CHD coronary heart disease
ER endoplasmic reticulum
ERAD endoplasmic reticulum associated degradation
FHBL familial hypobetalipoproteinemia
HBL hypobetalipoproteinemia
LDL-C LDL-cholesterol
LDL-R LDL-receptor
MTP microsomal triglyceride transfer protein
PERPP post-ER presecretory proteolysis
PCSK9 proprotein convertase subtilisin/kexin type 9
TC total cholesterol
TG triglyceride
1. Abstract
Hypobetalipoproteinemias (HBL) represent a heterogeneous group of dis-
orders characterized by reduced plasma levels of total cholesterol (TC), low
density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) below
the 5th percentile of the distribution in the population. HBL are defined as
primary or secondary according to the underlying causes. Primary monogenic
HBL are caused by mutations in several known genes (APOB, PCSK9,MTP,
SARA2) or mutations in genes not yet identified. Familial hypobetalipoprotei-
nemia (FHBL) is the most frequent monogenic form of HBL with a dominant
mode of inheritance. It may be due to loss-of-function mutations in APOB or,
less frequently, inPCSK9 genes. The rare recessive forms of primarymonogenic
HBL are represented by abetalipoproteinemia (ABL) and chylomicron reten-
tion disease (CMRD)due tomutations inMTP andSARA2 genes, respectively.
The clinical phenotype of heterozygous FHBL is usually mild, being frequently
characterized by fatty liver. The clinical phenotype of homozygous FHBL,
ABL, and CMRD is usually severe being characterized by intestinal lipid
malabsorption and fat-soluble vitamin deficiency. Secondary HBL are due to
several nongenetic factors such as diet, drugs, and disease-related conditions.
The aim of this review is to discuss the biochemistry, genetics, and clinical
spectrumofHBLand to provide a clinical and laboratory diagnostic algorithm.
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2. Introduction
HBL include a heterogeneous group of disorders characterized by reduced
plasma levels of TC, LDL-C, and apoB below the 5th percentile of the
distribution in the population. LDL, previously known as beta-lipoprotein,
plays a key role in the transport of hydrophobic neutral lipids (mainly
cholesterol) throughout the body. Since apoB is the main structural protein
component of LDL, this lipoprotein class belongs to apoB-containing lipo-
proteins which also include plasma very low density lipoproteins (VLDL)
and chylomicrons (CM) [1].
HBL may be caused by mutations in several known genes or mutations in
unidentified genes (primary monogenic HBL) and by several nongenetic
factors such as diet, drugs, and disease-related conditions (secondary
HBL). In primary HBL, the biochemical phenotype segregates as an autoso-
mal dominant or a recessive trait. The diagnosis of dominant HBL is driven
by the multigenerational presence of related individuals carrying the bio-
chemical HBL trait (low LDL-C and apoB plasma levels). The diagnosis of
recessive HBL is primed by the presence, early in life, of the biochemical
HBL trait associated with a generally severe clinical phenotype in offsprings
of normolipidemic parents. Dominant HBL includes FHBL (OMIM
107730), recessive HBL includes ABL (OMIM 200100) and CMRD
(OMIM 246700)—also called Anderson’s disease [1,2].
The spectrum of the clinical features in primary HBL ranges from absence
or paucity of symptoms to a very severe syndrome (e.g., Section 7). In
general, the genetic or acquired mechanisms that may reduce LDL-C and
apoB plasma levels and cause primary or secondary HBL, respectively, must
alter the production, assembly, secretion, or catabolism of apoB-containing
lipoproteins.
This chapter critically reviews the current knowledge on the pathophysio-
logy, molecular genetics, and clinical features of HBL, and describes a
diagnostic approach that may be helpful in a clinical setting.
3. Pathways of apoB-Containing Lipoproteins Production
3.1. ASSEMBLY AND SECRETION OF APOB-CONTAINING LIPOPROTEINS
Liver and intestine are the main site of production of apoB-containing
lipoproteins. apoB is expressed primarily in liver and intestine and plays a
central role in the transport and metabolism of plasma cholesterol and
triglycerides (TG) [1]. In human plasma, apoB occurs in two forms: apoB-
100 and apoB-48, which are encoded by the same gene (APOB) located on
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chromosome 2. apoB-100 (the full-length translation product of apoB
mRNA) is a large monomeric protein of 4536 amino acids that is synthesized
in the liver. apoB-100 is an essential component of liver-derived VLDLs,
IDLs, and LDLs, where it serves as ligand for the LDL-receptor (LDL-R).
apoB-48, a peptide consisting of the N-terminal 2152 amino acids of apoB-
100 (corresponding to 48% of apoB-100), is synthesized by the intestine and
is essential for CM production, the lipoproteins that transport dietary lipids.
apoB-48 results from a posttranscriptional modification of apoB mRNA
(mRNA editing), which converts a glutamine codon at position 2153 into a
stop codon [1]. apoB is essential for the production of apoB-containing
lipoproteins. Naturally occurring mutations in APOB gene that result in
structurally abnormal apoBs (e.g., apoB truncated at the C-terminal end)
are associated with a reduction of plasma levels of apoB-containing lipopro-
teins [1–3] (e.g., Section 4.1.1).
The assembly of VLDL in the liver and CM in the intestine occurs
cotranslationally (during the synthesis of apoB): while the C-terminal end
of apoB is still being synthesized, the N-terminal portion is translocated
across the endoplasmic reticulum (ER) and is assembled as small lipoprotein
particles for correct targeting to the pathways of lipoprotein secretion.
The apoB is targeted to the ER via the signal sequence (spanning amino
acids 1–27); its translocation occurs through the translocon, a proteinaceus
channel in the ER membrane [4,5].
3.2. CONTROL OF THE SECRETION OF APOB-CONTAINING LIPOPROTEINS
In view of the essential role of apoB in the assembly and secretion of apoB-
containing lipoproteins, apoB levels are regulated at multiple levels. Several
factors influence the translocation process of newly synthesized apoB. Most
relevant is the availability of lipids at the site of apoB synthesis in the ER,
which appears to dictate the amount of apoB secreted. In addition, the
process of translocation is affected by the characteristics of apoB itself,
including length, signal peptide polymorphism, and apoB folding to attain
lipid-binding capability, which regulate its ability to assemble into lipopro-
teins [6]. Successful transport and correct conformation of apoB may lead to
its final secretion as a lipoprotein constituent. In the case of lipid shortage,
nascent apoB translocation into the ER lumen is inefficient and domains of
apoB are exposed to the cytosol, where newly synthesized apoB undergoes
rapid intracellular degradation (e.g., Section 3.3) [5]. The N-terminal assem-
bly of lipids onto apoB during translocation requires the microsomal triglyc-
eride transfer protein (MTP), an 894 amino acid protein located in the ER
lumen that is a component of a protein complex involved in the early stages
of apoB lipidation in liver and intestine [7]. MTP has been shown to bind to
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the first 1000 amino acids of apoB which form a domain capable of initiating
nascent lipoprotein assembly (i.e., capable of recruiting lipids and facilitating
the conversion of apoB into a buoyant lipoprotein particle) [8–12]. This
‘‘lipoprotein initiating’’ domain of apoB contains the regions spanning
amino acid residues 1–264 and 512–721 or 270–570 involved in the binding
with MTP [7,13]. The physical interaction between apoB and MTP is impor-
tant for the initiation of translocation of the nascent apoB chain and for the
cotranslational addition of lipids to this chain [4,5,7]. Via these mechanisms,
MTP is believed to avoid improper folding and premature degradation of
apoB. The crucial role of MTP in the assembly and secretion of apoB-
containing lipoproteins is substantiated by the observation that mutations
in theMTP gene, which abolish MTP activity, are the cause of ABL, a severe
recessive disorder in which VLDL and CM are not secreted (e.g., Section 5.1)
[7,14]. Pharmacological inhibition of MTP in cultured cells and in vivo results
in a dose-dependent inhibition of the secretion of apoB [15,16]. Recent
evidence suggests that, in addition to MTP, other molecules with lipid
transferase activity in the ER, chaperones, and modifying enzymes (such as
PDI, BiP, Grp94, chaperon-like lectins, and cyclophilin) in different subcel-
lular compartments may be involved in the lipoprotein formation [17].
The addition of lipids to apoB is believed to occur in two steps. In the first
step, a small amount of lipids is added to apoB during its translation and
translocation into the ER lumen. This initial lipidation prevents apoB deg-
radation and leads to the formation of a partially lipidated small lipoprotein
particle. In the second step, after apoB translation is completed, the bulk of
neutral lipids is added to the primordial lipoprotein particle to form a mature
particle [18,19]. The maturation of VLDLs and CMs, which starts in the ER,
is completed in the Golgi [20]. Mature VLDLs and CMs present in the lumen
of the smooth ER are transported from the ER via specialized vesicles to the
Golgi apparatus for secretion [21]. The transport through the secretory
pathway is mediated by the coat protein (COP) machinery. The COPII
complex functions in ER-derived vesicle formation for anterograde trans-
port. One of the subunits of the COPII complex (Sar1-GTPase) has been
found to be critical for the vesicular transport of apoB-containing lipopro-
teins in rat hepatoma cells [22]. COPII associates with apoB-containing
lipoprotein particles and forms ER-derived vesicles that initiate their intra-
cellular transport to the Golgi apparatus before release into the circulation
[22]. In humans there are two Sar1 proteins, designated Sar1a and Sar1b
(encoded by Sar1-ADP-ribosylation GTPase, SARA1 and SARA2 genes,
respectively), which differ by 20 amino acid residues. The role of Sar1b in
vesicular transport of apoB-containing lipoproteins was demonstrated by
the observation that mutations in the SARA2 gene are the cause of CMRD
[23]. Whether the Sar1a isoform plays a distinct role in the transport of
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apoB-containing lipoproteins (e.g., is specifically required for VLDL secre-
tion by the liver) is an appealing hypothesis that remains to be tested.
3.3. INTRACELLULAR DEGRADATION OF APOB AND SECRETION OF
APOB-CONTAINING LIPOPROTEINS
In contrast to most secreted proteins, the amount of apoB-containing
lipoproteins excreted by the cells is mostly regulated by apoB degradation
along the ER/Golgi secretory pathway. Targeting of apoB for degradation
occurs when: (i) lipid availability is reduced, (ii) MTP activity is low, (iii)
apoB is misfolded, or (iv) under cellular stress conditions. Two intracellular
apoB degradation mechanisms have been described: (i) ER associated degra-
dation (ERAD), catalyzed by the ubiquitin–proteasome system, occurs
cotranslationally via retrotranslocation when misfolded apoB is present in
the cell or lipid supply/availability is reduced; (ii) post-ER presecretory
proteolysis (PERPP), achieved by autophagy, which delivers oxidized, aggre-
gated apoB and partially assembled apoB lipoproteins to lysosomes for
destruction [24,25]. Thus, intracellular degradation of apoB reduces the
assembly and secretion of apoB-containing lipoproteins.
Another mechanism involved in the control of the secretion of apoB-
containing lipoproteins is the LDL-R-mediated degradation. LDL-R pro-
motes intracellular degradation of apoB-100 resulting in decreased secretion
of VLDL by the liver. LDL-R knockout mice secrete apoB at a higher rate
than control mice; this increase is prevented by overexpression of the LDL-R
[26]. An in vivo turnover study in humans demonstrated that complete
deficiency of the LDL-R is associated with an increased apoB production
rate [27]. In addition, some naturally occurring mutations in LDL-R have
been identified which cause retention of both the mutant LDL-R and apoB
within the ER [28]. Taken together, these observations suggest that the LDL-
R facilitates the retention of apoB in the ER and its presecretory degradation
and possibly also the reuptake of newly secreted apoB-containing lipopro-
teins on the cell surface.
3.4. CLEARANCE OF APOB-CONTAINING LIPOPROTEINS VIA LDL-RECEPTOR
Most of the LDL particles are cleared from plasma by the liver via the
LDL-R. LDL-R-mediated uptake and degradation of LDL is an important
determinant of the concentration of LDL in the plasma, as clearly demon-
strated by some monogenic disorders (autosomal dominant hypercholester-
olemias) affecting LDL-R activity/number or the capacity of LDL to bind
LDL-R. These disorders may result from: (i) loss-of-function mutations
of LDL-R gene (reducing the number of LDL-Rs or their function),
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(ii) mutations in APOB gene (reducing the affinity of apoB for the LDL-R),
or (iii) gain-of-function mutations of PCSK9 gene (resulting in a reduced
number of LDL-Rs on the cell surface) [29].
The role of PCSK9 gene in the regulation of LDL-R number (and the
regulation of plasma LDL level) has received great attention in recent years.
PCSK9 gene, located on chromosome 1, encodes a 692 amino acid protein
designated proprotein convertase subtilisin/kexin type 9 (PCSK9). This pro-
tein is mainly expressed in the liver where it is produced in the ER as a
precursor protein which undergoes cotranslational autocatalytic cleavage in
the Golgi to create the processed protease that is secreted. Cell culture and
animal models have established that the LDL-R is one of the main down-
stream targets of PCSK9. Secreted mature PCSK9 binds the LDL-Rs on the
surface of hepatocytes and promotes their internalization and degradation in
a post-ER complex [30,31]. Thus, PCSK9 exerts its effect on the posttransla-
tional regulation of LDL-R by controlling the LDL-R degradation and the
number of receptors available on the cell surface. The mechanism by which
PCSK9 reduces the number of LDL-R is only partially known. There is
evidence that the secreted form of PCSK9 binds directly to the first epidermal
growth factor-like repeat of the extracellular domain of the LDL-R. PCSK9
binding to this site is required for LDL-R degradation [32]. The ability of
PCSK9 to promote LDL-R degradation, however, is independent of its
catalytic activity [33]. PCSK9 would function as a chaperone molecule that
prevents LDL-R recycling to the plasma membrane from endosomes and/or
targets LDL-R to the lysosome for degradation [33].
4. Dominant Forms of Primary HBL
FHBL is the main form of dominant primary HBL. FHBL is a genetically
heterogeneous disorder which may be due to defective secretion or increased
catabolism of apoB-containing lipoproteins. The majority of FHBL patients
are heterozygotes; homozygous and compound heterozygous FHBL are very
rare.
4.1. FHBL DUE TO DEFECTIVE SECRETION OF APOB-CONTAINING LIPOPROTEINS
The main candidate gene in subjects with FHBL with a dominant inheri-
tance is the APOB gene. Approximately 50% of FHBL heterozygotes are
carriers of pathogenic mutations in the APOB gene (APOB-related FHBL)
[34]. A large number of APOB mutations have been reported to be the cause
of FHBL and novel mutations are continually being identified in FHBL
subjects [2,3,34,35].
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4.1.1. APOB Gene Mutations Producing Truncated APOBs
Most APOB gene mutations cause the formation of premature termina-
tion codons in the apoB mRNA. The translation of these mRNAs leads to
the formation of truncated apoBs of various size which, to a variable extent,
lose the capacity to form plasma lipoproteins in liver and/or intestine and to
export lipids from these organs [2,3,34–37]. Truncated apoBs may or may not
be detectable in plasma according to their size. Truncated apoBs longer than
apoB-29/30 (i.e., with a size corresponding to 29–30% of that of apoB-100,
according to a centile nomenclature) are detectable in plasma (by immuno-
blot with an anti-apoB antibody), as they are secreted into the plasma as
constituents of plasma lipoproteins. The detection of a truncated apoB in
plasma suggests the presence of a mutation located in a genomic region
spanning from exon 26 to exon 29 of APOB gene. Truncated apoBs shorter
than apoB-29/30, due to mutations located in the first 25 exons of APOB
gene, are not detectable in plasma, as they are not secreted [3,34,35]. These
short truncated apoBs account for 30% of all APOB mutations reported so
far in FHBL [34]. Heterozygous FHBL subjects carrying truncated apoBs
have a reduced production of apoB-containing lipoproteins in liver and, in
some cases, in the intestine, which prevents the formation of VLDL and CM,
respectively [38,39]. The production rate (in liver and intestine) of truncated
apoBs, as compared with the corresponding wild-type forms of apoB (apoB-
48 and apoB-100), is greatly reduced for two main reasons: (i) the reduced
lipid-binding capacity of structurally abnormal apoBs (notably short trunca-
tions) makes them prone to a rapid intracellular degradation, (ii) the presence
of premature stop codons in apoB mRNAs due to frameshift or nonsense
mutations may induce a rapid mRNA degradation (nonsense-mediated
mRNA decay). In addition, FHBL carriers of long apoB truncations,
which are secreted into the plasma, may have an increased removal of
truncated apoB-containing lipoproteins by the liver (via the LDL-R) [38]
or by the kidney via megalin receptor [40].
The plasma levels of LDL-C and apoB in FHBL heterozygotes carrying
truncated apoBs are less than 30% of the values found in age- and gender-
matched controls [3,34]. This reduction, which is far below the expected 50%
values, is due not only to the extremely low levels of the secreted truncated
forms of apoB but also to the reduced production rate of apoB-100 encoded
by the normal allele which is 70–75% lower than that found in normal
subjects [41,42]. The lower production of normal apoB-100 is the result of
a reduced synthesis combined with an increased intracellular degradation.
Very few FHBL homozygotes and compound heterozygotes have been
reported. In APOB-related FHBL homozygotes or compound heterozygotes
carrying apoB truncations, LDL-C and apoB are either not detectable
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(if both mutant alleles encode truncated apoB shorter than apoB-29/30) or
are 10–20% of the control values (if both mutant alleles or at least one mutant
allele encode(s) truncated apoBs longer than apoB-29/30) [34,43].
4.1.2. APOB Gene Mutations Producing Amino Acid
Substitutions in apoB
Few nonconservative amino acid substitutions in apoB have been reported
to be the cause of FHBL [44,45]. Two mutations, R463W and L343V, were
found to cosegregate with FHBL in two large Libanese kindred. These
mutations involve the N-terminal beta-alpha1 domain of apoB which con-
tains sequence elements shown to be important for the proper folding of
apoB [13,46], for the physical interaction between apoB and MTP (the
chaperone molecule required for apoB lipidation) [8,10] and for lipid recruit-
ment during lipoprotein assembly and secretion [9]. These missense muta-
tions are associated with a decreased secretion of the mutant apoBs that are
retained in the ER because of an increased binding to MTP [44,45]. Other
carriers of R463W have been recently identified in Italian, Dutch, and
Spanish FHBL subjects, suggesting that R463W may be a recurrent muta-
tion in the population [34,37]. Recently, other missense mutations have been
reported to be the cause of FHBL. Five missense APOB mutations located
within the N-terminal 1000 amino acids of apoB, namely A31P, G275S,
L324M, G912D, and G945S, were identified in heterozygous carriers of
FHBL in the Italian population. Among these mutations, the A31P substi-
tution in apoB completely blocked apoB-48 secretion when expressed in rat
hepatoma cells [47]. In contrast to the two missense mutations L343V and
R463W, the A31P mutant did not lead to ER retention as the aberrantly
folded protein is degraded intracellularly by proteasomes and autophago-
some/lysosome pathway [47].
Plasma levels of LDL-C and apoB in heterozygous carriers of the APOB
missense mutations are comparable with those present in FHBL due to apoB
truncations. The two homozygotes for the missense mutation R463W de-
scribed so far have barely detectable apoB-containing lipoproteins in plasma
[44] as observed in patients homozygotes/compound heterozygotes for short
truncated apoBs [43,48].
4.2. FHBL DUE TO INCREASED LIVER UPTAKE OF APOB-CONTAINING
LIPOPROTEINS VIA LDL-RECEPTOR
The large number of FHBL subjects in whom no APOB gene mutations
were found suggests that other genes are involved in the pathogenesis of
FHBL [3]. In the past few years, loss-of-function mutations in PCSK9 gene
emerged as possible cause of FHBL (PCSK9-related FHBL).
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Studies in mice had shown that the inactivation of PCSK9 gene [49] was
associated with a marked reduction of plasma cholesterol and LDL-C. This
effect was due to an increased plasma LDL clearance, secondary to an
increased number of LDL-Rs in the liver. This observation suggested that
loss-of-function mutations of PCSK9 in humans would increase the receptor-
mediated uptake and catabolism of plasma LDL, possibly resulting in re-
duced plasma level of LDL and a lipid phenotype similar to that found in
APOB-related FHBL (e.g., Section 4.1). This hypothesis was confirmed
when inactivating mutations in human PCSK9 (resulting in truncated pro-
teins) were discovered in different populations (African-American, African,
Caucasian, and Japanese populations) [50–54]. Heterozygous subjects carry-
ing the loss-of-function mutations causing PCSK9 truncations (C679X,
Y142X, A68fsL82X, and W428X) were found to have a reduction of plasma
LDL-C levels ranging from 30% to 70% [50–54]. One homozygote for C679X
and one compound heterozygote (Y142X/R97) were found to have an 80%
reduction of LDL-C with respect to control values [51,52,55].
Population studies have demonstrated that some amino acid substitutions
of PCSK9 (p.R46L, p.G106R, p.N157K, p.G236S, p.R237W, p.L253F, p.
A443T, and p.S462P) are associated with a significant but variable reduction
(ranging from 4% to 30%) in plasma levels of LDL-C [56–59]. All these
variants were found to be more frequent in hypocholesterolemic subjects;
however, only some of them were demonstrated to be loss-of-function muta-
tions in vitro. Taken together, these observations strongly suggest that in
humans, loss-of-function mutations of PCSK9 cause an FHBL phenotype by
increasing the hepatic uptake of LDL.
In subjects with PCSK9-related FHBL, the magnitude of reduction of
plasma LDL-C and apoB appears to be less striking than that observed in
subjects with APOB-related FHBL in whom the reduction usually ranges
from 60% to 80% with respect to control values [34].
PCSK9-related FHBL homozygotes or compound heterozygotes have a
less severe reduction of LDL-C and apoB with respect to APOB-related
FHBL homozygotes/compound heterozygotes [43,48,51,52].
Plasma levels of LDL-C and apoB show large interindividual variability in
FHBL heterozygotes, regardless of the gene involved (APOB or PCSK9)
[34,50,60] that may be due to environmental factors (notably the diet) or to
genetic factors affecting secretion and catabolism of apoB-containing
lipoproteins. For example, it was shown that apoE genotype accounts
for 15–60% of this variation in APOB-related FHBL heterozygotes
carrying truncated apoBs [61]. It is also possible that factors affecting intes-
tinal cholesterol absorption (i.e., variations in NPC1L1 gene) play a role in
regulating apoB and LDL-C concentration in plasma of FHBL subjects [62].
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4.3. PREVALENCE OF PRIMARY FHBL
Epidemiological data on the prevalence of primary FHBL are scarce. The
population frequency of heterozygous APOB-related FHBL has been esti-
mated to be 1 in 3000 [63]. Heterozygous PCSK9-related FHBL seems to be
rare among Caucasians, while in African-Americans this disorder due to the
two nonsense mutations (Y142X and C679X) has a prevalence of 2–2.6%
[50]. The prevalence of homozygous and compound heterozygous APOB-
and PCSK9-related FHBL is exceedingly rare [2,59].
5. Recessive Forms of Primary HBL
Two very rare primary monogenic HBLs, usually diagnosed in infancy,
segregate as autosomal recessive traits: ABL and CMRD. These disorders are
characterized by the complete absence of apoB-containing lipoproteins (ABL)
or by a selective absence of apoB-48-containing lipoproteins (CMRD) due to a
defective assemblyandsecretionof these lipoproteinsby liverand/or intestine [1].
5.1. ABETALIPOPROTEINEMIA
ABL is an ‘‘exceedingly rare’’ disorder that occurs in less than one in
1 million individuals.
The plasma lipid profile of ABL patients is characterized by extremely low
plasma levels of TC, VLDL, and LDL and an almost complete absence of
apoB-100 and apoB-48. ABL-obligate heterozygotes have normal plasma
lipids; in some cases, however, a mild reduction of TC and LDL-C has been
reported [14]. ABL is due to mutations in theMTP gene which is required for
the assembly and secretion of apoB-containing lipoproteins in both liver and
intestine (e.g., Section 3.2). A variety of mutations in this gene, located on
chromosome 4, have been described;most of them result in truncated proteins
devoid of function [14,48,64–68]. Some MTP missense mutations have also
been reported, which affect either the apoB-binding ability of MTP or its
interaction with other components of the protein complex; they are associated
with a milder form of the disease [65,66]. It is conceivable that the severity of
ABL phenotype is related to the residual activity of MTP and the capacity to
form VLDL and CM. The absence ofMTP activity leads to the accumulation
of large lipid droplets in the cytoplasm in hepatocytes and enterocytes.
5.2. CHYLOMICRON RETENTION DISEASE
CMRD is a very rare recessive disorder characterized by the selective
absence of apoB-48 in plasma, low plasma cholesterol, and fat-soluble vita-
mins. apoB-48-containing lipoproteins are not secreted into the plasma,
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neither fasting nor postprandially [1]. In CMRD the plasma levels of LDL-C
and apoB are 25–40% of the control levels [69].
Affected subjects have an inability to export dietary lipids as CMs, leading
to a marked accumulation of CM-like particles in membrane-bound com-
partments of enterocytes, which contain large cytosolic lipid droplets.
CMRD is due to mutations in the SARA2 gene belonging to the Sar1-
ADP-ribosylation factor family of small GTPases. The SARA2 gene, located
on chromosome 5, encodes the Sar1b protein, a single polypeptide of 198
amino acids [23,70] that is involved in the control of the intracellular traf-
ficking of CMs in COPII-coated vesicles. CMs are selectively recruited by the
COPII machinery for transport through the cellular secretory pathway
[21,22]. Thus, CMRD may arise as a result of defects in the transport of
CMs through the secretory pathway.
Up to now, 14 mutations in the SARA2 gene have been identified in
patients with the clinical diagnosis of CMRD-Anderson disease [23,71–74].
Missense mutations of SARA2 represent the most common cause of CMRD;
these mutations were found in the Sar1b b-sheets region and are predicted to
perturb the geometry of the guanosine diphosphate and guanosine triphos-
phate binding site of Sar1b [70]. Only two frameshift mutations have been
reported so far [72,74].
6. Primary Orphan FHBL
In a significant number of FHBL kindred, the search for causative muta-
tions in the candidate genes is often inconclusive. Orphan FHBL kindred in
which the HBL phenotype segregates as dominant trait have been studied by
linkage analysis in order to identify the causative genes. Susceptibility loci
have been identified in chromosomes 13q, 3p21.1-22, and 10 but no candi-
date genes have emerged so far [75–77].
7. Spectrum of Clinical Manifestations in Primary HBL
Monogenic hypobetalipoproteinemias are characterized by a wide spec-
trum of clinical features.
The clinical phenotypes of primary HBL due to defective secretion of
apoB-containing lipoproteins (APOB-related FHBL, ABL, and CMRD)
are highly variable, their severity being directly related to the degree of the
impairment of the production of apoB-100 and/or apoB-48 [3]. The clinical
phenotype is more severe in the primary recessive HBLs: in ABL and in
CMRD the impaired formation/secretion of apoB-48 explains the severe
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intestinal lipid malabsorption and the related disorders (such as the growth
retardation and the neurological manifestations caused by vitamin
E deficiency) [78,79]. ABL displays a cluster of severe clinical manifestations
such as malabsorption of dietary fat and fat-soluble vitamins, steatorrhea,
‘‘failure to thrive’’ and acanthocytosis that are present in infancy and child-
hood. Later in life, because of the deficiency of fat-soluble vitamins, coagulo-
pathy, posterior column neuropathy and myopathy, anemia, spinocerebellar
ataxia, and retinitis pigmentosa develop [78]. Few reports have documented a
possible association of ABL with ileal adenocarcinoma [80] and metastatic
spinal cord glioblastoma [81] and fatty liver was reported in some cases
[82,83].
In CMRD, the clinical phenotype is strictly related to the impaired capaci-
ty to form CMs after a fat-containing meal. This leads to the development of
steatorrhea, growth retardation, malnutrition, and an accumulation of lipid
droplets within the enterocyte [84,85]. No neurological symptoms have been
reported. However, the description of variable clinical phenotypes and a
weak genotype–phenotype correlation in CMRD suggest that this disease
might represent a more complex trait rather than a simple autosomal reces-
sive disorder [69,74,79].
FHBL heterozygotes are generally asymptomatic but most of them devel-
op fatty liver and sometimes a mild intestinal malabsorption [34,35]. FHBL
homozygotes or compound heterozygotes have fatty liver and may suffer
from severe fat malabsorption [43,48].
In homozygotes or compound heterozygotes of APOB-related FHBL
carrying truncated apoBs, the severity of the clinical phenotype depends on
the capacity of the truncated apoBs to bind lipids and to be secreted as
lipoprotein particles by liver and intestine. apoBs shorter than apoB-29/30
are degraded intracellularly, mimicking an ABL-like condition [43,48]. The
presence in these individuals of at least one mutant APOB allele producing
truncations longer than apoB-48 may allow the secretion of small amounts of
apoB-containing lipoproteins (specifically CMs), which contribute to miti-
gate the clinical phenotype [34,43]. In homozygotes/compound heterozygotes
for long truncations (truncations longer than apoB-48), the clinical pheno-
type is usually mild, being characterized only by fatty liver [34]. Heterozy-
gous APOB-related FHBL carrying short truncations (i.e., truncated apoBs
shorter than apoB-48) usually have fatty liver and mild intestinal lipid
malabsorption [34,86]; carriers of long truncations are generally asymptom-
atic but they tend to develop fatty liver [34]. Carriers of apoB missense
mutations may be asymptomatic or manifest mild fatty liver disease and
sometimes a mild fat malabsorption [44,45,47,87].
A common characteristic of the severe forms of primary HBL is fat-soluble
vitamin deficiency, including vitamin E, secondary to fat malabsorption.
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Before the introduction of high-dose vitamin (A, D, K, and E) therapy, the
majority of ABL patients did not survive past the third decade of life. The
long-term vitamin treatment in ABL patients [78] was able to arrest
the progression of the neurological complications, especially when initiated
before the 16th month of life [88]. The current standard treatment for ABL,
which can be extended to CMRD and homozygous FHBL, is based on a low
fat diet eventually supplemented with medium-chain triglyceride and the
administration of fat-soluble vitamins [79].
The rare cases of PCSK9-related FHBL homozygotes, despite a substan-
tial reduction of plasma LDL-C (0.36–0.41 mmol/l), appear to be in good
health since they are free of gastrointestinal symptoms and detectable in-
crease in hepatic TG [51,52]. FHBL heterozygotes carrying PCSK9 muta-
tions are completely asymptomatic in contrast with APOB-related FHBL.
This difference is probably due to the biochemical pathways underlying
PCSK9- and APOB-related FHBL. Increased hepatic catabolism of LDL
present in PCSK9-related FHBL does not result in lipid accumulation
within the hepatocytes or entherocytes, while such an accumulation is a key
feature in the disorders characterized by defective assembly/secretion of
apoB-containing lipoproteins (APOB-related FHBL, ABL, and CMRD).
8. Main Clinical Issues of FHBL
8.1. FHBL AND FATTY LIVER DISEASE
In APOB-related FHBL the presence of fatty liver has been documented
by abdominal ultrasound examination, magnetic resonance, or liver biopsy
[89–93]. In FHBL heterozygous carriers of truncated forms of apoB, the
mean liver TG content is approximately fivefold that of controls with a great
interindividual variability despite similar apoB truncations and similar mea-
sures of obesity and glucose tolerance; this could indicate that other modifier
genes than APOB may affect the magnitude of hepatic TG accumulation
[94]. Histologically fatty liver of FHBL is similar to nonalcoholic fatty liver
disease, which is highly prevalent in the general population, often being
associated with obesity, dyslipidemia, hypertension, insulin resistance, type
2 diabetes mellitus; all these features, when clustered, characterize the meta-
bolic syndrome [95,96]. In contrast to metabolic syndrome, in FHBL subjects
the increased hepatic fat content is neither associated with glucose intoler-
ance nor with insulin resistance [97].
The pathophysiology of fatty liver in APOB-related FHBL has been
elucidated in animal models: apoB truncation-inducing mutations lead to
the production of VLDL particles smaller than normal, with reduced
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capacities to bind TG; in addition apoB-100 produced by the normal allele is
also reduced. The two combined defects of the VLDL export system produce
the accumulation of TG in hepatocytes [98,99].
Fatty liver is also present in FHBL heterozygotes carrying missense muta-
tions of APOB; these mutant apoBs are poorly lipidated and secreted as
lipoprotein particles, causing an impaired export of hepatic TG [25].
The long-term outcome of fatty liver in FHBL is still unknown; anecdotal
reports have documented an association between fatty liver and steatohepa-
titis, liver cirrhosis and hepatocarcinoma in FHBL patients [86,89–91,100].
Interestingly, fatty liver is not present in other forms of primary HBL such as
PCSK9-related FHBL [51] and the orphan FHBL (linked to chromosomes 3
and 10 loci) [76,77].
8.2. FHBL AND CARDIOVASCULAR DISEASE
Elevated LDL-C is a major risk factor for cardiovascular disease (CVD).
A recent meta-analysis of 61 prospective studies demonstrated that higher
TC levels were associated with higher risks of coronary heart disease (CHD)
and that there is no lower threshold. The association is log-linear suggesting
that greater LDL-C absolute reductions should be associated with greater
proportional reductions in risk of CHD [101]. In view of the low plasma
LDL-C levels, it is reasonable to assume that primary HBL subjects: (i) might
be naturally protected against CVD owing to reduced life-time exposure to
atherogenic apoB-containing lipoproteins and (ii) represent a unique setting
to verify the effects of a lifelong exposure to very low levels of LDL-C on the
development of cardiovascular atherosclerosis-related diseases. To date no
prospective studies have tested this hypothesis mainly because of the rela-
tively small size of existing FHBL case series. Recently 14 APOB-related
FHBL subjects have been clinically evaluated and found to be completely
free from CVD [37]. A study designed to assess the noninvasive surrogate
markers of CVD in FHBL showed that heterozygous APOB-related FHBL
subjects (no. 41) were found to have a significant decrease in arterial stiffness
as compared to control subjects, despite an increased prevalence of tradition-
al cardiovascular risk factors [102].
Convincing evidence of the protection of lifelong reduction of
plasma LDL-C has emerged with the observation that individuals with
PCSK9-related FHBL have a marked reduction of CHD risk. Cohen et al.
[103] examined the effect of PCSK9 loss-of-function mutations associated
with reduced plasma levels of LDL-C on the incidence of CHD in a large
population (Atherosclerosis Risk in Communities Study, ARIC). During a
15-year follow-up period among the carriers of the C679X mutation and the
R46L variants, there was an 88% and a 47% reduction in the risk of CHD,
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respectively. These findings represent a strong ‘‘proof of concept’’ in favor of
earlier initiation of lifestyle or, when appropriate, of drug interventions to
lower LDL-C levels.
8.3. FHBL AND CANCER
The association between low plasma cholesterol concentrations and
increased risk of cancer has been reported in several studies and it has been
explained as an example of ‘‘reverse causality’’ (subclinical cancer could
reduce cholesterol levels) [104–106]. To test whether long-term low plasma
cholesterol levels may increase cancer risk, cancer incidence has been eval-
uated in the ARIC study, among PCSK9-related FHBL [107]. There was no
evidence that cholesterol-lowering variants of PCSK9 were associated with
increased risk of total cancer.
9. Secondary Hypobetalipoproteinemias
Environmental factors and several diseases may contribute to reduce the
LDL-C and apoB plasma levels.
Vegetarians who do not eat meat, fish, diary, or eggs have mean plasma TC
and LDL-C levels lower than expected values of the control population. TC
and LDL-C average plasma levels are 3.10–3.36 and 1.55–1.81 mmol/l,
respectively, which are very close to the 5th percentile of the population
distribution [108,109].
In patients with chronic parenchymal liver disease, lipid and lipoprotein
plasma levels tend to be reduced [110]. The TC and LDL-C decrease paral-
lels, the impairment of the hepatic synthesis due to the progressive liver
failure [111]. Among cirrhotic patients classified according to the MELD
score which determines the residual liver function, TC ranges between 3.88
and 2.58 mmol/l and LDL-C between 2.07 and 1.29 mmol/l [112].
Conditions like chronic pancreatitis (adults) and cystic fibrosis (children)
are characterized by intestinal fat malabsorption which is associated with
HBL. In these common diseases, exocrine pancreatic insufficiency causes
steatorrhea when pancreas function is below 5% of normal function. Patients
with chronic pancreatitis suffer from malabsorption and nutritional deficien-
cies. In advanced disease, TC and LDL-C are generally low, 3.10–4.14 and
1.81–2.33 mmol/l, respectively [113]. In cystic fibrosis, the presence of pan-
creatic insufficiency is associated with lower levels of TC (2.58–2.32 mmol/l)
and LDL-C (1.29–1.81 mmol/l) [114].
In end-stage renal disease patients on hemodialysis, the LDL-C distribu-
tion curve is shifted to the left [115]; malnutrition and inflammation are
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believed responsible for the hypocholesterolemia associated with this
condition [116].
Hyperthyroidism exhibits an enhanced excretion of cholesterol, a reduced
output of hepatic VLDL and an increased turnover of LDL resulting in a
decrease of plasma TC and LDL-C [117,118]. Low plasma levels of TC have
been frequently described in a variety of hematologic disorders characterized
by the presence of anemia [119]. The existence of HBL has been reported in
all phenotypes of beta-thalassemia with TC and LDL-C levels in homo- and
heterozygotes about 50% lower compared with healthy controls [120,121].
The mechanisms underlying the hypocholesterolemia observed in beta-thal-
assemia patients are unknown, and several explanations have been proposed:
anemia, liver dysfunction, increased cholesterol consumption by the bone
marrow, hyper-stimulation of the LDL-R by inflammatory cytokines, or an
overactive reticuloendothelial system [122]. Hypocholesterolemia has also
been documented in Sickle cell disease patients and it recognizes the same
putative mechanisms as beta-thalassemia [123,124].
Hypocholesterolemia has been associated with cancer; there is no cause–
effect relationship but the so-called unsuspected sickness phenomenon
[125,126]: subclinical disease may lower cholesterol levels by a LDL-R hy-
peractivity in tumor cells [127].
10. Conclusions
The plasma levels of LDL-C and apoB below the 5th percentile of the
reference population’s values represent the biochemical landmark which
drives the clinical diagnosis of monogenic hypobetalipoproteinemias. The
magnitude of plasma LDL-C and apoB reduction is affected by: (i) the mode
of transmission, dominant (APOB- or PCSK9-related FHBL) versus reces-
sive (ABL and CMRD) and (ii) the heterozygous or homozygous state in the
case of FHBL (Table 1).
The first step in the differential diagnosis of HBL is the exclusion of the
secondary forms of HBL that are associated with a variety of clinical
conditions.
If the clinical diagnosis suggests primary HBL, the study of the transmis-
sion of HBL trait in the family of the index case provides a guide for the
molecular diagnosis. A mild clinical phenotype (moderate reduction of TC,
LDL-C, and apoB possibly associated with fatty liver), when combined with
the presence of the HBL trait in family members, strongly suggests the
clinical diagnosis of heterozygous FHBL. A diagnosis of possible FHBL
should also be considered in a subject with a mild phenotype whenever the
mode of transmission of HBL trait is undefined (i.e., it cannot be ascertained
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on firm bases). A severe clinical phenotype (extremely low or undetectable
levels of LDL-C and apoB associated with intestinal fat malabsorption and
severe fatty liver), notably in children or young adults, suggests the clinical
diagnosis of ABL, CMRD, or homozygous FHBL. In case of recessive
transmission of the HBL trait, FHBL may be excluded and the differential
diagnosis is restricted to ABL and CMRD.
The analysis of candidate genes may reveal the presence of pathogenic
mutations (e.g., frameshift, nonsense mutations, or missense mutations
known to be pathogenic) or other rare sequence variants with unknown
biological effect. In the latter case, the molecular diagnosis remains unde-
fined until cosegregation of the mutant allele with HBL is demonstrated or
in vitro functional studies of the mutant allele are available.
It should be emphasized that approximately 50% of individuals with the
clinical diagnosis of heterozygous FHBL do not have mutations in the two
major candidate genes (APOB and PCSK9) (Orphan FHBL) [34]. This
suggests that other major genes affecting the metabolism of apoB-containing
lipoproteins remain to be identified.
The flow chart shown in Fig. 1 is provided to guide the clinicians in the
identification of the etiology and the molecular bases of HBL.
Addendum
After the submission of the present review, a novel phenotype of primary
HBL, designated Familial Combined Hypolipidemia, was reported
(Musunuru K et al. N. Engl. J. Med 2010, 363.2220-2227). This disorder,
characterized by low plasma levels of LDL-C, TG and HDL-C, was identi-
fied in two siblings who were compound heterozygotes for two distinct
nonsense mutations in ANGPTL3 (encoding the angiopoietin-like 3 protein).
This finding indicates that loss of function mutations of ANGPTL3 are a
novel cause of monogenic HBL.
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Hypobetalipoproteinemia (HBL)
Plasma lipid profile
mild or severe clinical phenotype
Mode of transmission
Dominant
APOB gene
sequencing
APOB-related FHBL
SARA2 gene
sequencing CMRD
ABLMTP gene
sequencing
PCSK9 gene
sequencing
Orphan HBLNegative
Negative
Negative
Positive
Positive
No Yes
PCSK9 -related FHBL
Negative Positive
Recessive Undefined
Malabsorption
Malnutrition
Hyperthyroidism
Liver diseases
Cancer
Etc.
Secondary HBL
Severe phenotype*
Mild phenotype**
Primary HBL
with or without
(TC, LDL-C, apoB < 5th percentile)
FIG. 1. Flow-chart for the diagnosis of hypobetalipoproteinemias. Mild phenotype** indi-
cates a reduction of plasma TC, LDL-C, and apoB, without relevant clinical manifestations
apart from fatty liver. Severe phenotype* indicates a substantial reduction of plasma TC, LDL-
C, and apoB associated with clinical manifestations such as intestinal fat malabsorption, growth
retardation, fat-soluble vitamins deficiency, severe fatty liver, and possibly neurological disor-
ders. Undefined mode of transmission refers to those HBL cases in which no family history is
available. ABL, abetalipoproteinemia; CMRD, chylomicron retention disease; FHBL, familial
hypobetalipoproteinemia; HBL, hypobetalipoproteinemia.
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